Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2

通过共同靶向 VEGF 和 Ang2 重新编程肿瘤微环境以改善胶质母细胞瘤的免疫治疗

基本信息

  • 批准号:
    10394968
  • 负责人:
  • 金额:
    $ 40.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

SUMMARY Glioblastoma (GBM) is a universally fatal brain tumor. Immune checkpoint blockers (ICBs), such as anti- programmed cell death-1 protein (aPD1), alone or in combination with bevacizumab - an anti-vascular endothelial growth factor antibody (aVEGF), failed to improve survival in phase III clinical trials in GBM. This failure is, in part, due to the formidable barriers that the GBM tumor microenvironment (TME) creates. First, GBM tumor cells are highly proliferative and invasive with low neoantigen load, and thus, can easily evade immune surveillance. Second, GBM vessels are abnormal, and thus, they create a leaky, hypoxic and edematous TME and limit the delivery of drugs and the access of antitumor immune cells such as cytotoxic T lymphocytes (CTLs) into the tumor resulting in a cold CTL-excluded TME. Moreover, limited number of CTLs that accrue within GBM TME are dysfunctional. In contrast, pro-tumor immune cells such as regulatory T cells (Tregs) and “M2-like” macrophages preferentially accumulate in GBM. Unlike CTLs, Tregs and “M2-like” macrophages do not require intact vessels for trafficking to the tumor and thrive and proliferate in the GBM TME. Third, our pilot studies indicate that aPD1 aggravates vascular abnormalities and inflammatory responses in GBM, causing toxicities. Collectively, these features give rise to a strongly immunosuppressive TME in GBM that resists both the standard of care (SoC) and immunotherapy. Our preclinical and clinical studies and those of others indicate that angiopoietin-2 (Ang-2) can shorten the duration of aVEGF-induced vascular normalization. Thus, we hypothesize that normalizing tumor vasculature by co-targeting angiopoietin-2 (Ang-2) and aVEGF (abbreviated as aA2V) can both overcome resistance to aPD1 and reduce toxicities in patients with GBM. We will test if aA2V+aPD1 can durably normalize tumor vessels and improve their function. At cellular level, we will test if aA2V+aPD1 can repair the dysfunctional endothelial cells to express adhesion molecules, which are required for CTL cell trafficking, convert them to non-canonical antigen presenting cells to present tumor antigens to CTLs, and collectively result in improved CTL infiltration and function (Aim 1). We will further determine the involvement of antibody- dependent cell cytotoxicity (ADCC) in aPD1-induced adverse events and their alleviation by aA2V (Aim 2). Finally, we will use our newly developed surgical model that faithfully recapitulates GBM therapy in mice including SoC (surgery and chemo radiation) to test whether combining SoC with aA2V+aPD1 can promote durable responses (longer survival and memory responses) (Aim 3). Our findings will provide unprecedented insights into the mechanisms of resistance to immunotherapy in GBM, establish a novel strategy to overcome this resistance while abrogating putative adverse effects, and directly inform the design of clinical trials of GBM patients with combination aA2V+aPD1 therapy and SoC.
摘要 胶质母细胞瘤(GBM)是一种常见的致命性脑肿瘤。免疫检查点阻滞剂(ICB),如抗- 程序性细胞死亡-1蛋白(APD1),单独或与抗血管内皮细胞的贝伐单抗联合应用 生长因子抗体(AVEGF)在GBM的III期临床试验中未能提高存活率。这一故障是在 部分是由于GBM肿瘤微环境(TME)造成的强大屏障。首先,基底膜肿瘤细胞 具有高度增殖性和侵袭性,新抗原载量低,因此很容易逃脱免疫监视。 其次,基底膜血管是异常的,因此,它们会造成渗漏、缺氧和水肿性TME,并限制 药物的传递和抗肿瘤免疫细胞如细胞毒性T淋巴细胞(CTL)进入肿瘤的途径 导致冷的CTL排除的TME。此外,GBM TME内累积的有限数量的CTL是 功能失调。相比之下,促肿瘤免疫细胞,如调节性T细胞(Tregs)和类M2巨噬细胞 优先积累在GBM中。与CTL不同,Tregs和“M2样”巨噬细胞不需要完整的血管 贩运到肿瘤并在GBM TME中茁壮成长和增殖。第三,我们的初步研究表明,aPD1 加重GBM中的血管异常和炎症反应,导致毒副作用。总而言之,这些 特征导致GBM中的TME具有强烈的免疫抑制作用,可同时抵抗标准护理(SOC)和 免疫疗法。我们的临床前和临床研究以及其他研究表明,血管生成素-2(Ang-2)可以 缩短血管内皮细胞生长因子诱导的血管正常化时间。因此,我们假设正常化的肿瘤 通过共同靶向血管生成素-2(Ang-2)和aVEGF(简称aA2V)的血管形成系统可以同时克服 GBM患者对aPD1的耐药性和减毒作用。我们将测试aA2V+aPD1是否能够持久 使肿瘤血管正常化,改善其功能。在细胞水平上,我们将测试aA2V+aPD1是否可以修复 功能障碍的内皮细胞表达CTL细胞运输所需的黏附分子,转化为 将肿瘤抗原递呈给CTL,并共同导致 改进了CTL的渗透和功能(目标1)。我们将进一步确定抗体是否参与- APD1诱导的不良事件中的依赖细胞细胞毒性(ADCC)以及aA2V的缓解作用(目标2)。 最后,我们将使用我们新开发的手术模型,它忠实地概括了小鼠的GBM治疗。 包括SoC(手术和化疗),以测试SoC与aA2V+aPD1结合是否可以促进 持久反应(更长的生存和记忆反应)(目标3)。我们的发现将提供前所未有的 对GBM免疫治疗耐药机制的洞察,建立克服这一问题的新策略 在消除可能的不良反应的同时产生耐药性,并直接指导GBM临床试验的设计 AA2V+aPD1联合SOC组。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dai Fukumura其他文献

Dai Fukumura的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dai Fukumura', 18)}}的其他基金

Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
通过共同靶向 VEGF 和 Ang2 重新编程肿瘤微环境以改善胶质母细胞瘤的免疫治疗
  • 批准号:
    10582613
  • 财政年份:
    2021
  • 资助金额:
    $ 40.34万
  • 项目类别:
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment
重新设计肥胖引起的异常微环境以改善 PDAC 治疗
  • 批准号:
    9403496
  • 财政年份:
    2017
  • 资助金额:
    $ 40.34万
  • 项目类别:
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers
克服结直肠癌抗 VEGF 治疗的耐药性
  • 批准号:
    8463132
  • 财政年份:
    2013
  • 资助金额:
    $ 40.34万
  • 项目类别:
Doppler Optical Frequency Domain Imaging Instrument
多普勒光频域成像仪
  • 批准号:
    7793981
  • 财政年份:
    2010
  • 资助金额:
    $ 40.34万
  • 项目类别:
Surgical and Animal Core
外科和动物核心
  • 批准号:
    7118421
  • 财政年份:
    2006
  • 资助金额:
    $ 40.34万
  • 项目类别:
Vascular Normalization: Rolse of Perivascular Cells
血管正常化:血管周围细胞的旋转
  • 批准号:
    7118413
  • 财政年份:
    2006
  • 资助金额:
    $ 40.34万
  • 项目类别:
NO in Tumor Angiogenesis,Microcirculation & Rad.Therapy
NO在肿瘤血管生成、微循环中的作用
  • 批准号:
    7071781
  • 财政年份:
    2002
  • 资助金额:
    $ 40.34万
  • 项目类别:
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy
一氧化氮在肿瘤血管生成、微循环和放射治疗中的作用
  • 批准号:
    7618192
  • 财政年份:
    2002
  • 资助金额:
    $ 40.34万
  • 项目类别:
NO in Tumor Angiogenesis,Microcirculation & Rad.Therapy
NO在肿瘤血管生成、微循环中的作用
  • 批准号:
    6522149
  • 财政年份:
    2002
  • 资助金额:
    $ 40.34万
  • 项目类别:
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy
一氧化氮在肿瘤血管生成、微循环和放射治疗中的作用
  • 批准号:
    7812092
  • 财政年份:
    2002
  • 资助金额:
    $ 40.34万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 40.34万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 40.34万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 40.34万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 40.34万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 40.34万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 40.34万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 40.34万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 40.34万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 40.34万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 40.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了